INCYTE 54828-101 Advanced Malignancies - Clinical Trial

We are doing this study to find out the dose of the study drug INCB054828 that is safe and tolerable in people with advanced cancer.

Advanced cancers

Part 1: Adults with any advanced solid tumor malignancy.
Part 2: Adults with documented FGF/FGFR alteration.
Part 3: Adults (+/- FGF/FGFR alterations) and solid tumor malignancies for which gemcitabine + cisplatin, docetaxel, trastuzumab, and PD-1 treatment is relevant.

- Must provide archival tumor tissue or undergo a fresh tumor biopsy.

This study will be divided into three parts.

Part 1 is looking for the maximum tolerated dose of the study drug.
Part 2 will look at the dose selected from Part 1 in squamous non-small lung cancer, gastric cancer, urothelial cancer, endometrial cancer, multiple myeloma (MM), and myeloproliferative neoplasms (MPN).
Part 3 will look at the study drug in combination with gemcitabine and cisplatin, docetaxel, pembrolizumab, trastuzumab or INCMGA00012.

All patients will be required to:
- Provide multiple blood and urine samples during the study
- Come to the study center for a series of physical exams, tests and scans (Computerized tomography (CT) or Magnetic resonance imaging (MRI))
- Undergo an eye exam